Argyrodite is a key structure type for ion-transporting materials. Oxide argyrodites are largely unexplored despite sulfide argyrodites being a leading family of solid-state lithium-ion conductors, in which the control of lithium distribution over a wide range of available sites strongly influences the conductivity. We present a new cubic Li-rich (>6 Li + per formula unit) oxide argyrodite Li 7 SiO 5 Cl that crystallizes with an ordered cubic (P2 1 3) structure at room temperature, undergoing a transition at 473 K to a Li + site disordered F4̅ 3m structure, consistent with the symmetry adopted by superionic sulfide argyrodites. Four different Li + sites are occupied in Li 7 SiO 5 Cl (T5, T5a, T3, and T4), the combination of which is previously unreported for Li-containing argyrodites. The disordered F4̅ 3m structure is stabilized to room temperature via substitution of Si 4+ with P 5+ in Li 6+x P 1−x Si x O 5 Cl (0.3 < x < 0.85) solid solution. The resulting delocalization of Li + sites leads to a maximum ionic conductivity of 1.82(1) × 10 −6 S cm −1 at x = 0.75, which is 3 orders of magnitude higher than the conductivities reported previously for oxide argyrodites. The variation of ionic conductivity with composition in Li 6+x P 1−x Si x O 5 Cl is directly connected to structural changes occurring within the Li + sublattice. These materials present superior atmospheric stability over analogous sulfide argyrodites and are stable against Li metal. The ability to control the ionic conductivity through structure and composition emphasizes the advances that can be made with further research in the open field of oxide argyrodites.

No abstract

Objectives To compare the transection rate at the start and at the end of the FUE procedure. Materials and methods The study was conducted in a private setup in patients undergoing first session of FUE surgery over 2000 grafts. Six areas of 1 cm2 were marked, two in midline and two on either side. All the procedures were undertaken by the single surgeon to avoid any bias. At the start of the surgery, the extraction of hair was performed in areas A1, A2, and A3. All the excised hair and transected hair were counted. The surgery was then completed but the remaining three areas (B1, B2, and B3) were left intact. Later, FUE was done in these areas. The excised hair and transected hair were counted. All the data were analyzed statistically by paired t test. Results A total of 25 patients were included in the study. The mean age of the patients was 35.2 years. The transection rate was 5.3/cm2 in mid‐zone, 4.4/cm2 on right side, and 5.7/cm2 on left side at the start and 27.7/cm2 in mid‐zone, 25.6/cm2 on right side, and 24.2/cm2 on left side at the end. The transection rate increased from 5.03 to 6.0/cm2 for FUS <2500 but increased from 4.83 to 6.6/cm2 with FUs over 2500 and increased from 5.5 to 6.67/cm2 when FUs were over 3000. Conclusion The surgeon's workload increases the hair transection during FUE.

ObjectivesA recent systematic review confirmed the usefulness of fecal calprotectin (FC) in distinguishing organic (inflammatory bowel disease (IBD)) from non-organic gastrointestinal disease (irritable bowel syndrome (IBS)). FC levels <50 μg/g have a negative predictive value >92% to exclude organic gastrointestinal (GI) disease. Levels >250 μg/g correlate with endoscopic IBD disease activity; sensitivity 90%. We aimed to determine clinical outcomes in intermediate raised FC results (50–250 μg/g).SettingPrimary care general practices in Coventry and Warwickshire, and 3 secondary care hospitals.Participants443 FC results in adults (>16 years old) were reviewed from July 2012 to October 2013. Clinical data was collected from hospital databases and general practitioners. Long-term clinical data was available in 41 patients (out of 48).Primary and secondary outcome measuresThe number of new diagnoses of IBD, IBS and other diagnoses for the intermediate group. The number referred and discharged from secondary care.ResultsA new IBD diagnosis was made in 19% (n=8) of intermediate results (1% of normal and 38% of raised results). 5% (n=2) of intermediate results had known IBD in remission. A new IBS diagnosis was made in 27% (n=11) of intermediate results, while 34% (n=14) remained undiagnosed, although 8 of these were not referred to secondary care.ConclusionsFC testing remains useful in aiding diagnosis of organic GI conditions. However, unlike negative and strongly positive FC results, intermediate FC results lead to a mixture of diagnoses. The OR of a new diagnosis of IBD for an intermediate result compared to normal FC result was 26.6, while an intermediate FC result gave an OR of 0.54 for a new IBS diagnosis compared to normal FC. For intermediate FC results, 1 in 3 patients remained in secondary care after 12 months with an OR of 3.6 compared to a normal FC result.

The PRP injections can increase the hair diameter.